View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 22, 2020updated 12 Jul 2022 11:48am

UK researchers start trial of hydroxychloroquine to prevent Covid-19

Researchers at the University of Oxford in the UK are leading an international clinical trial to assess hydroxychloroquine for potentially preventing Covid-19 in frontline healthcare workers.

Researchers at the University of Oxford in the UK are leading an international clinical trial to assess hydroxychloroquine for potentially preventing Covid-19 in frontline healthcare workers.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The double-blind, randomised, placebo-controlled trial has opened for participants at Oxford University Hospitals (OUH) in Oxford and Brighton on 21 May 2020.

Named COPCOV, the trial is led by the University of Oxford-supported Mahidol Oxford Tropical Medicine Research Unit (MORU) in Bangkok. It is designed to recruit 40,000 frontline healthcare workers and staff in Europe, Africa, Asia and South America.

COPCOV co-principal investigator Nicholas White said: “Covid-19 is a major risk for frontline healthcare workers around the world. We really do not know if chloroquine or hydroxychloroquine are beneficial or harmful against Covid-19.

“The best way to find out if they are effective in preventing Covid-19 is in a randomised clinical trial. That’s what COPCOV is, and why we’re doing this study.”

The Diabetes Trial Unit at the Churchill Hospital is managing the UK part of the study, which will be initially conducted at 25 sites across the country.

Following OUH and Brighton, four more sites are set to open by the end of this month, and a total of 25 by the end of next month.

Diabetes Trial Unit head Amanda Adler said: “We’ll be using the extensive experience we already have in running large international trials to run the COPCOV trial across the UK which will initially include 25 sites.

“So far, there is no drug or vaccine that has been shown to prevent Covid-19 vaccination, and we’ll be working closely with our MORU, Brighton, and Oxford University colleagues to find out if hydroxychloroquine can lower the risk of getting Covid-19 in UK health workers.”

Trial participants will be given hydroxychloroquine or placebo for three months. Results are expected to be available by the end of the year.

Earlier this week, researchers in Australia launched a clinical trial to assess hydroxychloroquine for the prevention of Covid-19 in healthcare workers who are at high risk.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena